Legislative Developments

State Advocacy

MOS President Testifies Against Missouri HJR 117

Dr-Joe-Muscato-Testifying-240x175On March 22, 2022, President of the Missouri Oncology Society (MOS) Joseph Muscato, MD, FACP, Missouri Cancer Associates, testified against HJR 117, which if signed into law, would allow the legislature to turn down funding for Medicaid Expansion yearly, putting our patients at risk—each year—of losing coverage.

Additionally, the bill would place work reporting requirements on those in the expansion population, creating bureaucratic barriers and additional access challenges for patients with cancer, potentially causing Medicare patients to lose their healthcare.

MOS believes expansion will go a long way in providing greater access to cancer screening, diagnosis, and treatment for Missourians. Last month, MOS and the Association for Clinical Oncology wrote a letter to Chairman Cody Smith and members of the House Budget Committee expressing concern with HJR 117 and the seriously negative consequences it could have on patients with cancer.

MOS strongly opposes HJR 117 and believes that no individual diagnosed with cancer should be without health insurance that guarantees access to high-quality cancer care.


Federal Advocacy

MOS Issues Protest Letter to Payers on IV Iron Therapy Policy

July 13, 2022

The Missouri Oncology Society (MOS) issued a letter protesting payer policies that direct providers to use only one type of intravenous iron therapy.

The policy’s economic considerations seem to focus on product acquisition costs only and fail to take into account the multitude of issues that increase costs to the patient and provider.

Read the Letter 

MOS Joins 400+ Organizations in Support of MCED Legislation

May 5, 2022

The Missouri Oncology Society (MOS) joined more than 400 organization from all 50 states to urge Congress to pass the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act (H.R.1946/S.1873) this year. This legislation would create a pathway for MCED tests to be covered by the Medicare program following approval by the Food and Drug Administration (FDA).

Read the Letter 


Oncology State Societies at ACCC: Snapshot from the 2022 ASCO Annual Meeting

In this clip, Stephanie Van Winkle, Executive Director of the Oncology State Societies at ACCC, gives an overview of the important work the Oncology State Societies does to empower its members around state and federal advocacy issues, and help them support cancer care delivery in their state. Join today

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us